nimorazole has been researched along with Cancer of Head in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 7 (26.92) | 29.6817 |
| 2010's | 14 (53.85) | 24.3611 |
| 2020's | 3 (11.54) | 2.80 |
| Authors | Studies |
|---|---|
| Baumann, M; Besso, MJ; Bitto, V; Koi, L; Krause, M; Kurth, I; Linge, A; Löck, S; Möbius, L; Overgaard, J; Pfeifer, M; Valentini, C; Weise, C; Yaromina, A; Zips, D | 1 |
| Grimm, P; Söderman, M | 1 |
| Andersen, M; Eriksen, JG; Hansen, CR; Jensen, K; Overgaard, J; Saksø, M | 1 |
| Bar-Deroma, R; Castadot, P; Christiaens, M; Collette, S; Giralt, J; Grant, W; Gregoire, V; Hurkmans, CW; Kazmierska, J; Monti, AF; Overgaard, J; Tomsej, M; Weber, DC | 1 |
| Ajmal Ali, M; Akilarasan, M; Al-Hemaid, FMA; Chen, SM; Cheng, YH; Kogularasu, S; Liu, X; Mani, V; Umamaheswari, R | 1 |
| Alsner, J; Andersen, E; Andersen, LJ; Evensen, JF; Grau, C; Hansen, HS; Hoff, CM; Johansen, J; Lassen, P; Overgaard, J; Overgaard, M; Specht, L | 1 |
| Alsner, J; Busk, M; Horsman, MR; Olthof, N; Overgaard, J; Speel, EJ; Sørensen, BS | 1 |
| Frederiksen, KD; Metwally, MA; Overgaard, J | 1 |
| Baines, H; Bolton, S; Miles, E; Slevin, N; Thomson, D; West, C; Yang, H | 1 |
| Hassan Metwally, MA; Jansen, JA; Overgaard, J | 1 |
| Andersen, LJ; Bentzen, J; Eriksen, JG; Overgaard, J; Primdahl, H; Toustrup, K | 1 |
| Ali, R; Grau, C; Hassan Metwally, MA; Iqbal, K; Kuddu, M; Overgaard, J; Prasad, R; Shouman, T; Strojan, P | 1 |
| Ali, R; Grau, C; Hassan Metwally, MA; Kuddu, M; Overgaard, J; Shouman, T; Strojan, P | 1 |
| Alsner, J; Eriksen, JG; Hamilton-Dutoit, S; Lassen, P; Overgaard, J; Tramm, T | 1 |
| Andersen, L; Bentzen, J; Eriksen, JG; Evensen, JF; Grau, C; Hansen, HS; Hoff, CM; Johansen, J; Lassen, P; Overgaard, J; Overgaard, M; Specht, L | 1 |
| Alsner, J; Lassen, P; Overgaard, J; Sørensen, BS; Toustrup, K; Wiuf, C | 1 |
| Bishop, K; Henk, JM; Shepherd, SF | 1 |
| Andersen, E; Andersen, L; Bastholt, L; Bentzen, J; Evensen, JF; Grau, C; Hansen, HS; Hansen, O; Johansen, J; Overgaard, J; Overgaard, M; Specht, L | 1 |
| Alsner, J; Eriksen, JG; Horsman, MR; Nordsmark, M; Overgaard, J | 1 |
| Corvò, R | 1 |
| Alsner, J; Eriksen, JG; Gebski, V; Horsman, MR; Nordsmark, M; Overgaard, J | 1 |
| Eriksen, JG; Overgaard, J | 1 |
| Bjarnason, NH; Christiansen, M; Specht, L | 1 |
| Bishop, K; Cottrill, CP; Henk, JM; Walton, MI | 1 |
| Berthelsen, A; Jørgensen, K; Lindeløv, B; Overgaard, J; Overgaard, M; Rasmusson, B; Sand Hansen, H | 1 |
| Cohen, MS; Mukerji, R; Samadi, AK; Timmermann, BN; Tong, X; Zhang, H | 1 |
1 review(s) available for nimorazole and Cancer of Head
| Article | Year |
|---|---|
Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Evidence-Based Medicine; Head and Neck Neoplasms; Humans; Nimorazole; Radiotherapy, Conformal | 2007 |
14 trial(s) available for nimorazole and Cancer of Head
| Article | Year |
|---|---|
DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, lary
Topics: Carcinoma, Squamous Cell; Cisplatin; Dose Fractionation, Radiation; Feasibility Studies; Head and Neck Neoplasms; Humans; Hypopharynx; Larynx; Middle Aged; Mouth; Neoplasm Recurrence, Local; Nimorazole; Oropharynx; Papillomavirus Infections | 2020 |
Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure.
Topics: Benchmarking; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Nimorazole; Organs at Risk; Prospective Studies; Quality Assurance, Health Care; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2017 |
DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Darbepoetin alfa; Disease-Free Survival; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Hemoglobins; Humans; Male; Middle Aged; Nimorazole; Oxygen; Patient Compliance; Radiation-Sensitizing Agents; Squamous Cell Carcinoma of Head and Neck | 2018 |
NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer.
Topics: Antitrichomonal Agents; Carcinoma, Squamous Cell; Cell Hypoxia; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Nimorazole; Radiation-Sensitizing Agents; Radiotherapy, Intensity-Modulated; Research Design; Squamous Cell Carcinoma of Head and Neck | 2014 |
Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nimorazole; Squamous Cell Carcinoma of Head and Neck | 2015 |
IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Dose Fractionation, Radiation; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hypoxia; Male; Middle Aged; Neoplasm Staging; Nimorazole; Patient Compliance; Radiation-Sensitizing Agents; Squamous Cell Carcinoma of Head and Neck | 2015 |
Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - results from the randomized DAHANCA 5 and 7 trials.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Erythrocyte Transfusion; Female; Head and Neck Neoplasms; Hemoglobins; Humans; Male; Middle Aged; Nimorazole; Radiotherapy; Survival Analysis | 2011 |
Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; Cell Hypoxia; Chi-Square Distribution; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nimorazole; Predictive Value of Tests; Proportional Hazards Models; Radiation-Sensitizing Agents; Survival Rate | 2012 |
Treatment of head and neck cancer with CHART and nimorazole: phase II study.
Topics: Adult; Aged; Brachytherapy; Carcinoma, Squamous Cell; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Nimorazole; Palliative Care; Prognosis; Radiation Dosage; Risk Assessment; Survival Analysis; Terminally Ill; Treatment Outcome | 2003 |
Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Denmark; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nimorazole; Proportional Hazards Models; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2003 |
Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Cell Hypoxia; Child; Double-Blind Method; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nimorazole; Osteopontin; Placebos; Radiation-Sensitizing Agents; Sialoglycoproteins; Survival Analysis | 2005 |
Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Hypoxia; Combined Modality Therapy; Drug Screening Assays, Antitumor; Female; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Middle Aged; Nimorazole; Osteopontin; Oxygen; Prospective Studies; Radiation-Sensitizing Agents; Risk Assessment | 2007 |
Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer.
Topics: Carcinoma, Squamous Cell; Dose Fractionation, Radiation; Drug Administration Schedule; Head and Neck Neoplasms; Humans; Nimorazole; Pilot Projects; Radiation-Sensitizing Agents | 1998 |
Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85.
Topics: Carcinoma; Combined Modality Therapy; Denmark; Double-Blind Method; Female; Head and Neck Neoplasms; Humans; Male; Nimorazole; Radiation-Sensitizing Agents | 1991 |
11 other study(ies) available for nimorazole and Cancer of Head
| Article | Year |
|---|---|
Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts.
Topics: Chemoradiotherapy; Head and Neck Neoplasms; Heterografts; Humans; Hypoxia; Nimorazole; Prognosis; Squamous Cell Carcinoma of Head and Neck | 2023 |
Phlegmasia cerulea dolens in a patient treated with carboplatin.
Topics: Aged; Carboplatin; Chemoradiotherapy; Female; Fibrinolytic Agents; Head and Neck Neoplasms; Heparin, Low-Molecular-Weight; Humans; Leg; Neoplasms, Squamous Cell; Neoplasms, Unknown Primary; Nimorazole; Surgical Procedures, Operative; Thrombophlebitis; Venous Thrombosis | 2020 |
One-pot synthesis of three-dimensional Mn
Topics: Antitrichomonal Agents; Biosensing Techniques; Carbon; Electrochemical Techniques; Electrodes; Head and Neck Neoplasms; Humans; Manganese Compounds; Nimorazole; Oxides; Tablets | 2017 |
Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells.
Topics: Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Head and Neck Neoplasms; Humans; Neoplasm Proteins; Nimorazole; Papillomaviridae; Radiation Tolerance; Squamous Cell Carcinoma of Head and Neck | 2013 |
Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
Topics: Adult; Aged; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Male; Medication Adherence; Middle Aged; Nimorazole; Radiation-Sensitizing Agents; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2014 |
Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nimorazole; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Squamous Cell Carcinoma of Head and Neck | 2015 |
Radiotherapy quality assurance of the IAEA-HypoX trial of the accelerated radiotherapy in the treatment of head and neck squamous cell carcinoma with or without the hypoxic radiosensitizer nimorazole.
Topics: Carcinoma, Squamous Cell; Dose Fractionation, Radiation; Guideline Adherence; Head and Neck Neoplasms; Humans; Medical Audit; Multicenter Studies as Topic; Nimorazole; Practice Guidelines as Topic; Quality Assurance, Health Care; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Retrospective Studies | 2015 |
HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antitrichomonal Agents; Carcinoma, Squamous Cell; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, p16; Head and Neck Neoplasms; Humans; Hypoxia; Male; Middle Aged; Neoplasm Staging; Nimorazole; Retrospective Studies; Treatment Outcome | 2010 |
Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.
Topics: Antigens, Neoplasm; Biomarkers; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Squamous Cell; Cell Hypoxia; Cells, Cultured; Disease-Free Survival; Follow-Up Studies; Head and Neck Neoplasms; Humans; Immunohistochemistry; Nimorazole; Predictive Value of Tests; Prognosis; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic | 2007 |
The nimorazole regimen in patients with head and neck cancer can increase the effect of vitamin K antagonists.
Topics: Aged; Aged, 80 and over; Drug Interactions; Female; Fibrinolysis; Glottis; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; International Normalized Ratio; Laryngeal Neoplasms; Male; Nimorazole; Vitamin K | 2008 |
Withaferin A, a cytotoxic steroid from Vassobia breviflora, induces apoptosis in human head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Argentina; Carcinoma, Squamous Cell; Cell Cycle; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Molecular Structure; Plants, Medicinal; Solanaceae; Withanolides | 2010 |